Apheresis Market

The global apheresis market in terms of revenue was estimated to be worth USD 2.6 billion in 2024 and is poised to reach USD 3.9 billion by 2029, growing at a CAGR of 8.8% from 2024 to 2029. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market.

Growth of the market is mainly driven by upsurge in demand for source plasma from biopharmaceutical companies, and increase in demand for blood components and growing concerns regarding blood safety.

Attractive opportunities in the Apheresis Market

To know about the assumptions considered for the study, Request for Free Sample Report

Apheresis Market Dynamics

DRIVER: Rise in number of chronic diseases across the globe

The upsurging prevalence of chronic diseases worldwide serves as a key driving factor in the expansion of the market. Chronic conditions are characterized by their prolonged duration and gradual progression, encompass a wide range of diseases such as cardiovascular diseases, diabetes, cancer, and autoimmune disorders. For instance, according to the Evidence-Based Practice of Palliative Medicine Second Edition released in 2023, nearly half of individuals aged 65 to 69 suffer from two or more chronic ailments, a figure that rises to 75% among those over 85. Thus, as the populations age and lifestyle patterns evolve, the incidence of chronic diseases continues to climb, generating heightened demand for advanced therapeutic solutions like apheresis. Apheresis procedures offer a precise method for managing diseases by removing harmful substances from the bloodstream. Moreover, with ongoing technological innovations and increasing awareness among healthcare professionals and patients, apheresis procedures are becoming more accessible and are being progressively incorporated into treatment methods for effectively managing chronic diseases. thus, increasing the growth of the market throughout the forecast period.

RESTRAINT: High cost of apheresis devices decreasing the adoption

The market faces a significant restraining factor in the form of the high cost associated with apheresis devices, which in turn impedes their widespread adoption. The substantial initial investment required to acquire apheresis devices presents a barrier to their adoption, particularly for smaller healthcare facilities or those operating in resource-constrained settings. Moreoer, the high cost of apheresis devices encompasses not only the purchase price but also maintenance, consumables, and specialized training for healthcare professionals. This financial burden may dissuade healthcare providers from investing in apheresis technology, limiting patient access to these potentially life-saving procedures. Additionally, concerns regarding the cost-effectiveness of apheresis treatments compared to alternative therapies or traditional blood banking methods may further impact adoption rates.

OPPORTUNITY: Apheresis for leukemia and pediatric patients

The growing adoption of mainly therapeutic apheresis, particularly in the treatment of diseases such as leukemia, presents a significant opportunity within the market, particularly for paediatric patients. For instance, in the US for 2024, the American Cancer Society projects approximately 62,770 new instances of leukemia across all subtypes, with an estimated 23,670 fatalities attributed to the disease. The apheresis process involves removing specific components from a patient's blood and returning the rest to the body. In the case of leukemia, therapeutic apheresis plays a crucial role in managing the disease by removing excess white blood cells, which are often malignant, from the patient's bloodstream. This process helps alleviate symptoms and can even contribute to remission in some cases, making it a vital component of leukemia treatment protocols. Additionally, apheresis allows for precise control over the removal of harmful cells, minimizing the risk of complications and reducing the need for aggressive interventions. This makes it a preferred option for many parents and healthcare providers seeking the best possible outcomes for paediatric leukemia patients, thus showing the lucrative growth of the market.

CHALLENGE: Safety of blood transfusion in developing countries

The safety of blood transfusions in developing countries poses a significant challenge for the market, primarily due to concerns surrounding the transmission of infectious agents such as HIV, HBV, and others. In many developing regions, blood transfusion services face various obstacles, including inadequate infrastructure, limited resources, and insufficient regulatory oversight. As a result, there is a heightened risk of transfusion-transmitted infections, which can have severe consequences for both patients and healthcare systems. Moreover, increasing prevalence of infectious diseases underscore the importance of addressing transfusion safety on a global scale. The emergence of new pathogens and the potential for outbreaks pose ongoing challenges for blood transfusion services, particularly in regions with limited capacity for screening and testing. Thus, the safety concerns of blood transfusion in developing countries is posing a challenge to the market.

Apheresis Market Ecosystem

Prominent companies in this market are market Terumo BCT, Inc. (Japan), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (US), Baxter International Inc. (US), Asahi Kasei Medical Co., Ltd. (Japan), B. Braun Melsungen AG (Germany), Cerus Corporation (US), Kaneka Corporation (Japan), SB-Kawasumi Laboratories, Inc (Japan), ), LMB Technologie GmbH (Germany), Bioelettronica S.r.l. (Italy), Infomed SA (Switzerland), Cytosorbents Corporation (US), Nikkiso Co., Ltd (Japan), Macopharma SA (France), Miltenyi Biotec (Germany), Otsuka Holdings Co., Ltd. (Japan), Medica S.p.A. (Italy), Mallinckrodt plc (Ireland), Becton, Dickinson and Company (US), Medicap clinic GmbH (Germany), Haier Biomedical (China), Beijing ZKSK Technology Co., Ltd. (China), Guangzhou Daji Medical Science and Technology Co. Ltd (China), PuriBlood Medical (Taiwan).

The Device segment is expected to grow at the highest CAGR from 2024 to 2029 in apheresis industry

Based on product, the apheresis market is segmented into apheresis devices and disposables. Among these the apheresis device segment is expected to show the growth of at the fastest rate. The apheresis device segment is again divided into two Sub-segments, centrifugation apheresis device and membrane separators. The centrifugation apheresis device holds the largest share in the apheresis device segment in 2023, attributing to several key advantages it offers over membrane separation technology. As centrifugation apheresis devices are known for their high efficiency in separating blood components, making them a preferred choice for therapeutic procedures hence, these are highly sought after by healthcare providers seeking comprehensive treatment options for various conditions, such as leukaemia, autoimmune disorders, and neurological diseases. This is leading to increasing adoption of centrifugation apheresis devices in hospitals, driving the growth of this segment within the market.

The plasmapheresis accounted for the largest share of the apheresis industry.

By application, the apheresis market is segmented into plasmapheresis, plateletpheresis, erythrocytapheresis, leukapheresis, photopheresis, and other applications including, lipidpheresis, lymphapheresis, immunoadsorption and stem cell collection. Among these, plasmapheresis segment accounted for the largest market share, attributing to its widespread adoption in the treatment of various neurological, immunological, and renal diseases. Plasmapheresis, also known as therapeutic plasma exchange, is a crucial therapeutic intervention utilized in the management of conditions such as Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), myasthenia gravis, thrombotic thrombocytopenic purpura (TTP), renal diseases, and rheumatic diseases. Its efficacy in removing harmful antibodies, immune complexes, and other pathogenic factors from the plasma makes it an indispensable treatment option for patients suffering from these debilitating illnesses. Thus, as the prevalence of neurological and autoimmune diseases continues to rise globally, the demand for plasmapheresis as a therapeutic intervention is expected to grow substantially, driving the expansion of this market segment.

Blood Collection Centers and blood component providers accounted for the largest share of the apheresis industry.

Based on end-users, the apheresis market is segmented into blood collection centers and blood component providers, hospitals and transfusion centers, and other end users including, emergency medical device providers, acute care centers, and medical & academic institutes. Among these, blood collection centers and blood component providers segment accounted for the largest share of the market, attributing to the rising demand for apheresis devices and related disposables within this segment. Blood collection centers and blood component providers play a pivotal role in the healthcare ecosystem by collecting, processing, and distributing blood products to meet the needs of patients undergoing various medical treatments, surgeries, and transfusions. As the demand for blood components such as plasma, platelets, and red blood cells continues to grow, these facilities require advanced apheresis technologies to efficiently collect and separate these components from whole blood donations. Thus, this rise in demand from blood collection centers and blood component providers is leading to increase the growth of the market over the forecast period.

North America accounted for the largest share of the apheresis industry in 2023.

To know about the assumptions considered for the study, download the pdf brochure

Based on the region, the apheresis market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America accounted for the largest share of the market. This is due to increase in prevalence of chronic diseases, such as cardiovascular diseases, cancer, and autoimmune disorders. This is leading to increased need for therapeutic interventions, including apheresis procedures, to manage these diseases effectively. As a result, healthcare facilities across North America increasingly rely on apheresis technologies to provide crucial treatment options for patients with chronic illnesses, thereby driving the market's growth. Moreover, rising instances of surgical procedures in North America further bolster the demand for apheresis products and services. As surgical interventions often require blood transfusions, necessitating the availability of adequate blood components like platelets and plasma. Apheresis plays a pivotal role in obtaining these specific blood components efficiently and safely, ensuring a steady supply for surgical procedures, thus contributing significantly to the dominance of North America in the market.

Prominent players in apheresis market include Terumo BCT, Inc. (Japan), Fresenius SE & Co. KGaA (Germany), Haemonetics Corporation (US), Baxter International Inc. (US), Asahi Kasei Medical Co., Ltd. (Japan), Medica S.p.A. (Italy), Mallinckrodt plc (Ireland), Becton, Dickinson and Company (US), LMB Technologie GmbH (Germany), Beijing ZKSK Technology Co., Ltd. (China), Guangzhou Daji Medical Science and Technology Co. Ltd (China), Bioelettronica S.r.l. (Italy), Infomed SA (Switzerland), Cytosorbents Corporation (US), Medicap clinic GmbH (Germany), Haier Biomedical (China), B. Braun Melsungen AG (Germany), Cerus Corporation (US), Kaneka Corporation (Japan), SB-Kawasumi Laboratories, Inc (Japan), Nikkiso Co., Ltd (Japan), Macopharma SA (France), Miltenyi Biotec (Germany), Otsuka Holdings Co., Ltd. (Japan), PuriBlood Medical (Taiwan).

Scope of the Apheresis Industry

The study categorizes the Apheresis Market to forecast revenue and analyze trends in each of the following submarkets:

By Product

• Apheresis disposables
• Apheresis devices
  • Centrifugal apheresis devices
  • Membrane separators

By Procedure

• Automated blood collection
• Therapeutic apheresis
  • Therapeutic apheresis disposables
    • Neurological disorders
    • Blood disorders
    • Renal disorders
    • Autoimmune disorders
    • Metabolic disorders
    • Cardiovascular disorders
    • Other disorders
  • Therapeutic apheresis devices

By Technology

• Centrifugation
  • Continuous flow centrifugation
  • Intermittent flow centrifugation
• Membrane separation

By Application

• Plasmapheresis
• Plateletpheresis
• Erythrocytapheresis
• Leukapheresis
• Photopheresis
• Other applications

By End User

• Blood collection centers and blood component providers
• Hospitals and transfusion centers
• Other end users

By Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • Italy
  • Spain
  • France
  • RoE
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • RoAPAC
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa
  • GCC Countries
  • Rest of Middle East and Africa

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst